Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity

被引:0
|
作者
Pedro Pinto
Paula Paulo
Catarina Santos
Patrícia Rocha
Carla Pinto
Isabel Veiga
Manuela Pinheiro
Ana Peixoto
Manuel R. Teixeira
机构
[1] Portuguese Oncology Institute of Porto (IPO Porto),Cancer Genetics Group, IPO Porto Research Center (CI
[2] Portuguese Oncology Institute of Porto (IPO Porto),IPOP)
[3] University of Porto,Department of Genetics
来源
Breast Cancer Research and Treatment | 2016年 / 159卷
关键词
HBOC; Next-generation sequencing; Targeted sequencing;
D O I
暂无
中图分类号
学科分类号
摘要
Molecular diagnosis of hereditary breast and ovarian cancer (HBOC) by standard methodologies has been limited to the BRCA1 and BRCA2 genes. With the recent development of new sequencing methodologies, the speed and efficiency of DNA testing have dramatically improved. The aim of this work was to validate the use of next-generation sequencing (NGS) for the detection of BRCA1/BRCA2 point mutations in a diagnostic setting and to study the role of other genes associated with HBOC in Portuguese families. A cohort of 94 high-risk families was included in the study, and they were initially screened for the two common founder mutations with variant-specific methods. Fourteen index patients were shown to carry the Portuguese founder mutation BRCA2 c.156_157insAlu, and the remaining 80 were analyzed in parallel by Sanger sequencing for the BRCA1/BRCA2 genes and by NGS for a panel of 17 genes that have been described as involved in predisposition to breast and/or ovarian cancer. A total of 506 variants in the BRCA1/BRCA2 genes were detected by both methodologies, with a 100 % concordance between them. This strategy allowed the detection of a total of 39 deleterious mutations in the 94 index patients, namely 10 in BRCA1 (25.6 %), 21 in BRCA2 (53.8 %), four in PALB2 (10.3 %), two in ATM (5.1 %), one in CHEK2 (2.6 %), and one in TP53 (2.6 %), with 20.5 % of the deleterious mutations being found in genes other than BRCA1/BRCA2. These results demonstrate the efficiency of NGS for the detection of BRCA1/BRCA2 point mutations and highlight the genetic heterogeneity of HBOC.
引用
收藏
页码:245 / 256
页数:11
相关论文
共 50 条
  • [41] Hidden etiology of cerebral palsy: genetic and clinical heterogeneity and efficient diagnosis by next-generation sequencing
    Rosello, Monica
    Caro-Llopis, Alfonso
    Orellana, Carmen
    Oltra, Silvestre
    Alemany-Albert, Marta
    Marco-Hernandez, Ana V.
    Monfort, Sandra
    Pedrola, Laia
    Martinez, Francisco
    Tomas, Miguel
    PEDIATRIC RESEARCH, 2021, 90 (02) : 284 - 288
  • [42] The diverse heterogeneity of molecular alterations in prostate cancer identified through next-generation sequencing
    Wyatt, Alexander W.
    Mo, Fan
    Wang, Yuzhuo
    Collins, Colin C.
    ASIAN JOURNAL OF ANDROLOGY, 2013, 15 (03) : 301 - 308
  • [43] Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing
    Jung-Yun Lee
    Jung-Ki Yoon
    Boyun Kim
    Soochi Kim
    Min A Kim
    Hyeonseob Lim
    Duhee Bang
    Yong-Sang Song
    BMC Cancer, 15
  • [44] Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing
    Lee, Jung-Yun
    Yoon, Jung-Ki
    Kim, Boyun
    Kim, Soochi
    Kim, Min A.
    Lim, Hyeonseob
    Bang, Duhee
    Song, Yong-Sang
    BMC CANCER, 2015, 15
  • [45] The Clinical Utility Of Next-Generation Sequencing In The Diagnosis Of Hereditary Hemolytic Anemias
    Nussenzveig, Roberto H.
    Sangle, Nikhil
    Christensen, Robert D.
    Salama, Mohamed E.
    Prchal, Josef
    Yaish, Hassan
    Agarwal, Archana M.
    BLOOD, 2013, 122 (21)
  • [46] Diagnostics of Hereditary Connective Tissue Disorders by Genetic Next-Generation Sequencing
    Pope, Marita Knudsen
    Ratajska, Aleksandra
    Johnsen, Hilde
    Rypdal, Karoline Bjarnesdatter
    Sejersted, Yngve
    Paus, Benedicte
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2019, 23 (11) : 783 - 790
  • [47] Experience with the targeted next-generation sequencing in the diagnosis of hereditary hypophosphatemic rickets
    Turan, Ihsan
    Erdem, Sevcan
    Kotan, Leman Damla
    Dilek, Semine Ozdemir
    Tastan, Mehmet
    Gurbuz, Fatih
    Bisgin, Atil
    Bayazit, Aysun Karabay
    Topaloglu, Ali Kemal
    Yuksel, Bilgin
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2021, 34 (05): : 639 - 648
  • [48] Clinical utility of next-generation sequencing in the diagnosis of hereditary haemolytic anaemias
    Agarwal, Archana M.
    Nussenzveig, Roberto H.
    Reading, Noel S.
    Patel, Jay L.
    Sangle, Nikhil
    Salama, Mohamed E.
    Prchal, Josef T.
    Perkins, Sherrie L.
    Yaish, Hassan M.
    Christensen, Robert D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (05) : 806 - 814
  • [49] Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.
    Offit, Kenneth
    Schrader, Kasmintan A.
    Maxwell, Kara Noelle
    Vijai, Joseph
    Hart, Steven
    Thomas, Tinu
    Wubbenhorst, Bradley
    Ravichandran, Vignesh
    Moore, Raymond
    Hu, Chunling
    Lilyquist, Jenna
    Shimelis, Hermela
    Slavin, Thomas Paul
    Domchek, Susan M.
    Robson, Mark E.
    Szabo, Csilla
    Neuhausen, Susan L.
    Weitzel, Jeffrey N.
    Couch, Fergus J.
    Nathanson, Katherine L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Molecular portraits of metastatic breast cancer using tissue next-generation sequencing
    Shah, Ami N.
    Davis, Andrew A.
    Carroll, Kristen J.
    Wehbe, Firas
    Behdad, Amir
    Cristofanilli, Massimo
    CANCER RESEARCH, 2020, 80 (04)